
Medeia has built a versatile network of international academic and corporate collaborators and service providers. Importantly, we have several years’ of experience in strategic business relationships. Medeia’s business strategy has been vetted in partnership with a leading Scandinavian pharmaceutical company, Orion Corp.
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with over 90 years of history. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients as well as diagnostic tests for global markets. Orion's pharmaceutical R&D focuses on drugs for CNS disorders, cancer, critical care and pulmonary drugs for administration with the Easyhaler® inhaler. Medeia and Orion have been collaborating since 2007 under a research and option agreement on novel NCEs targeting human neurodegenerative diseases discovered by Medeia.
Medeia Therapeutics Ltd has been awarded a 0,65 million euro grant from Young Innovative Company (YIC) program financed by Tekes.
Read more...
Medeia Therapeutics receives significant support from Finnish Funding Agency for Technology and Innovation (Tekes)
Read more...
Medeia Therapeutics announces the second financing round led by Inveni Capital
Read more...